Abstract Background: Highly purified Cannabidiol (CBD, epidiolex) is approved for treating Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis…
Abstract Introduction: Effectiveness and tolerability of plant-derived highly purified cannabidiol (CBD) in patients with Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS),…
Abstract Background: Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) are severe, treatment-refractory, epileptic encephalopathies that often develop in infancy or…
Abstract Retrospective chart review of CBD use in patients with LGS and DS in a UK EAP. CBD retention for…
Abstract Background: Dravet Syndrome (DS) is a rare and severe form of childhood epilepsy that is often refractory to conventional…
Abstract Objectives: Stiripentol, fenfluramine, and cannabidiol are licensed add‐on therapies to treat seizures in Dravet Syndrome (DS). There are no…
Abstract Dravet Syndrome (DS) is a developmental epileptic encephalopathy characterized by drug-resistant seizures and other clinical features, including intellectual disability…
Abstract OBJECTIVE: The objective of this systematic review with meta-analysis was to evaluate the efficacy, safety, and short- and long-term…
Abstract Dravet syndrome is a severe developmental and epileptic encephalopathy mostly caused by heterozygous mutation of the SCN1A gene encoding…
Abstract Cannabidiol (CBD), a chemical found in the Cannabis sativa plant, is a clinically effective antiepileptic drug whose mechanism of…